- In March 2025, Starpharma Holdings Limited announced the completion of enrolment and all patient follow-up visits in its phase 2 study of VivaGel for treating bacterial vaginosis (BV). The study evaluated the effectiveness of VivaGel, administered once daily for seven days, in treating BV, with 132 participants enrolled in the US. Data is currently being processed, and results are expected to be available in the second quarter of this year.
- In November 2024, Freya Biosciences announced a strategic investment of USD 10.4 million from the Bill & Melinda Gates Foundation, along with an additional USD 1.4 million in funding from current investor Export and Investment Fund of Denmark (EIFO). The funds will be utilized to develop microbial immunotherapies for treating bacterial vaginosis (BV), aiming to address pre-term birth and potentially other conditions impacting maternal and newborn health.
- In January 2024, Organon announced the availability of XACIATO (clindamycin phosphate) vaginal gel 2% by prescription for the treatment of bacterial vaginosis (BV). BV occurs when certain bacteria overgrow, disrupting the natural vaginal microbiome and causing symptoms such as odour and discharge. Research has also shown that BV disproportionately affects non-Hispanic Black and Mexican American women.
- In March 2022, Organon and Daré Bioscience, Inc. announced a partnership in which Organon will acquire the global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). XACIATO is an FDA-approved treatment for bacterial vaginosis (BV) in females aged 12 and older.
- In December 2021, Daré Bioscience, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved XACIATO (clindamycin phosphate vaginal gel, 2%) (previously called DARE-BV1) for the treatment of bacterial vaginosis in females aged 12 years and older.
